Remove 2020 Remove Safety Remove Side effects
article thumbnail

Endometriosis market projected to grow at a CAGR of 10% between 2020 and 2030

Pharmaceutical Technology

The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.

article thumbnail

Navigating the Regulatory Environment of Pharmaceutical Marketing: Balancing Patient Safety and Industry Innovation

Pharma Marketing Network

Pharmaceutical marketing is a critical aspect of the industry, as it helps in spreading awareness about the benefits and potential side effects of different drugs. In conclusion, navigating the regulatory environment of pharmaceutical marketing requires a delicate balance between patient safety and industry innovation.

Safety 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK approves Moderna’s bivalent COVID-19 vaccine

European Pharmaceutical Review

The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. In each dose of the booster vaccine, ‘Spikevax bivalent Original/Omicron’, half of the vaccine (25µg) targets the original virus strain from 2020 and the other half (25µg) targets the Omicron variant.

Safety 105
article thumbnail

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

After the vaccine was found to meet the standards of safety and quality, the regulatory agency granted the authorisation. According to the safety monitoring, side effects were generally mild and self-resolving, as well as in line with those reported for the original Moderna booster dose. 1 Omicron variant of concern.

article thumbnail

Thursday pharma headlines

World of DTC Marketing

million in 2020, more than double the number in 2015, according to health data company IQVIA. The company decided there were too few reports of serious depression and suicidal behavior and not enough specifics about those cases to warrant more than “routine” monitoring of safety data. Annual U.S.

Pharma 180
article thumbnail

Is DTC effective?

World of DTC Marketing

During the first quarter of 2020, the number of telehealth visits increased by 50%, compared with the same period in 2019, with a 154% increase in visits noted in surveillance week 13 in 2020, compared with the same period in 2019. What are the side effects? That belief is out the window.

article thumbnail

Briumvi may struggle to make headway in crowded multiple sclerosis market

Pharmaceutical Technology

Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017). All three treatments are monoclonal antibodies. Some 48% of patients on Briumvi also suffered with infusion reactions.